Journal Information
Vol. 43. Issue 2.
Pages 86-91 (February 2007)
Share
Share
Download PDF
More article options
Vol. 43. Issue 2.
Pages 86-91 (February 2007)
Original Article
Full text access
Lung Transplantation and the Development of Diabetes Mellitus in Adult Patients With Cystic Fibrosis
Visits
4324
María Soledad Navas de Solís, Juan Francisco Merino Torres
Corresponding author
merino_jfr@gva.es

Correspondence: Dr. J.F. Merino Torres. Servicio de Endocrinología y Nutrición. Hospital Universitario La Fe. Avda. Campanar, 21. 46009 Valencia. España
, Isabel Mascarell Martínez, Francisco Piñón Sellés
Servicio de Endocrinología y Nutritión, Hospital Universitario La Fe, Valencia, Spain
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Objective

The prevalence of diabetes mellitus is higher in patients with cystic fibrosis than in the general population. Solid organ transplantation is a significant risk factor for diabetes mellitus, which has been linked to type of immunosuppression. The aim of this study was to analyze whether lung transplantation represents a significant risk factor for the onset of abnormal carbohydrate metabolism in cystic fibrosis, whether it affects severity of alterations, and whether there is a relation to type of immunosuppression.

Patients and Methods

The following data were extracted retrospectively for 54 patients with cystic fibrosis: type of carbohydrate metabolism alteration and treatment received, whether or not transplantation took place, and type of immunosuppression used.

Results

Twenty of the 54 patients (37%) underwent lung transplantation; 18 of them (89%) developed diabetes mellitus. Eight of the patients (24%) who did not receive a lung developed diabetes and 10 (29%) displayed carbohydrate intolerance (P<.01, χ2 test). Insulin was administered to 36.3% of nontransplanted patients and 78.6% of transplanted patients. The influence of immunosuppressant used was analyzed in 15 patients. Nine out of 10 patients (90%) treated with cyclosporine and 4 out of 5 (80%) of those treated with tacrolimus developed diabetes mellitus. All received the same regimen of corticosteroid therapy.

Conclusions

For cystic fibrosis patients, lung transplantation is a significant risk factor for developing abnormal carbohydrate metabolism and it influences severity and treatment. No significant differences in the frequency of development of diabetes mellitus were found in relation to type of immunosuppression.

Key words:
Cystic-fibrosis-related diabetes
Diabetes and cystic fibrosis
Post-transplantation diabetes mellitus
Objetivo

La prevalencia de diabetes mellitus (DM) en pacientes con fibrosis quistica (FQ) es mayor que en la poblacion general.

El trasplante de organos solidos es un factor de riesgo importante para el desarrollo de DM y se ha relacionado con el tipo de inmunodepresion. El objetivo del estudio ha sido analizar si el trasplante pulmonar (TP) es un factor de riesgo importante para desarrollar alteracion hidrocarbonada en la FQ, si influye en su gravedad y tratamiento, y si existe relacion con el tipo de inmunodepresion.

Pacientes y Métodos

Se estudio retrospectivamente a 54 pacientes adultos con FQ, sobre los que se recogieron los siguientes datos: tipo de alteracion hidrocarbonada y su tratamiento, existencia o no de TP y tipo de inmunodepresion.

Resultados

De los 54 pacientes, 20 recibieron TP (37%). De estos, el 89% (n = 18) presento DM. Entre aquellos que no recibieron TP, el 24% (n = 8) presento DM y el 29% (n = 10) intolerancia hidrocarbonada (p < 0,01; prueba de χ2). Se pauto insulina al 36,3% de los pacientes sin TP y al 78,6% de los trasplantados. La influencia de la inmunodepresion se analizo en 15 pacientes. Desarrollaron DM el 90% (9/10) de los tratados con ciclosporina y el 80% (4/5) de los tratados con tacrolimus. Todos llevaban la misma pauta de corticoterapia.

Conclusiones

El TP es un factor de riesgo importante para el desarrollo de alteracion hidrocarbonada en pacientes con FQ e influye en su gravedad y tratamiento. No hemos encontrado diferencia significativa entre el tipo de inmunodepresion y la aparicion de DM.

Palabras clave:
Fibrosis quistica
Diabetes relacionada con fibrosis quistica
Diabetes mellitus postrasplante
Full text is only aviable in PDF
REFERENCES
[1]
SM Rowe, S Miller, EJ Sorscher.
Mechanisms of disease: cystic fibrosis.
N Engl J Med, 352 (2005), pp. 1992-2001
[2]
R Barrio Castellanos, A Cos Blanco, E Garcia Garcia, M Gussinye Canadell, JF Merino Torres, MT Munoz Calvo.
Consenso sobre diagnostico y tratamiento de las alteraciones del metabolismo hidrocarbonado en la fibrosis quistica.
An Esp Pediatr, 53 (2000), pp. 573-579
[3]
S Tofe, JC Moreno, L Maiz, M Alonso, H Escobar, R Barrio.
Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis.
Eur J Endocrinol, 152 (2005), pp. 241-247
[4]
JP van Hooff, MH Christiaans, EM van Duijnhoven.
Evaluating mechanisms of post-transplant diabetes mellitus.
Nephrol Dial Transplant, 19 (2004), pp. 8-12
[5]
M First, D Gerber, S Hariharan, DB Kaufman, R Shapiro.
Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management.
Transplantation, 73 (2002), pp. 379-386
[6]
D Hadjiliadis, J Madill, C Chaparro, A Tsang, TK Waddell, LG Singer, et al.
Incidence and prevalence of diabetes mellitus in patients with cystic fibrosis undergoing lung transplantation before and after lung transplantation.
Clin Transplant, 19 (2005), pp. 773-778
[7]
M Albareda, J Rodriguez-Espinosa, M Murugo, A de Leiva, R Corcoy.
Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test.
Diabetologia, 43 (2000), pp. 1507-1511
[8]
RW Holl, C Buck, C Babka, A Wolf, A Thon.
HbAlc is not recommended as a screening test for diabetes in cystic fibrosis.
Diabetes Care, 23 (2000), pp. 126
[9]
A Moran, D Hardin, D Rodman, HF Allen, RJ Beall, D Borowitz, et al.
Diagnosis, screening and management of cystic fibrosis related diabetes mellitus. A consensus conference report.
Diabetes Res Clin Pract, 45 (1999), pp. 61-73
[10]
JA Davidson, A Wilkinson.
On behalf of the International Expert Panel on New-Onset Diabetes After Transplantation. New-onset diabetes after transplantation 2003 International Consensus Guidelines: an endocrinologist's view.
Diabetes Care, 27 (2004), pp. 805-812
[11]
J Davidson, A Wilkinson, J Dantal, F Dotta, H Haller, D Hernandez, et al.
New-onset diabetes after transplantation: 2003 International Consensus Guidelines.
Transplantation, 75 (2003), pp. 3-24
[12]
MP Solomon, DC Wilson, M Corey, D Kalnins, J Zielenski, LC Tsui, et al.
Glucose intolerance in children with cystic fibrosis.
J Pediatr, 142 (2003), pp. 128-132
[13]
AD Mackie, SJ Thornton, FP Edenborough.
Cystic fibrosis-related diabetes.
Diabet Med, 20 (2003), pp. 425-436
[14]
R Barrio Castellanos.
Trastomos en el metabolismo hidrocarbonado en la fibrosis quistica.
Hormona y Factores de Crecimiento, 8 (2005),
[15]
S Quattmcci, M Rolla, G Cimino, S Bertasi, S Cingolani, F Scalercio, et al.
Lung transplantation for cystic fibrosis: 6-year follow-up.
J Cys Fibres, 4 (2005), pp. 107-114
[16]
B Yung, FH Noormohamed, M Kemp, J Hooper, AF Iant, ME Hodson.
Cystic fibrosis-related diabetes: the role of peripheral insulin resistance and beta-cell dysfunction.
Diabet Med, 19 (2002), pp. 221-226
[17]
DS Hardin, A Ieblanc, G Marshall, DK Seilheimer.
Mechanisms of insulin resistance in cystic fibrosis.
Am J Physiol Endocrinol Metab, 281 (2001), pp. E1022-E1028
[18]
DS Hardin, A Ieblanc, L Para, DK Seilheimer.
Hepatic insulin resistance and defects in substrate utilization in cystic fibrosis.
Diabetes, 48 (1999), pp. 1082-1087
[19]
MD Piero Marchetti.
New-onset diabetes after transplantation.
J Heart Lung Transplant, 23 (2004), pp. S194-S201
[20]
JA Paolillo, G Boyle, Y Iaw, S Miller, K Iawrence, K Wagner, et al.
Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression.
Transplantation, 71 (2001), pp. 252-256
[21]
BL Kasiske, JJ Zinder, D Gilbertson, AJ Matas.
Diabetes mellitus after kidney transplantation in the United States.
Am J Transplant, 3 (2003), pp. 178-185
[22]
O Heisel, R Heisel, R Balshaw, P Keown.
New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis.
Am J Transplant, 4 (2004), pp. 583-595
[23]
F Kur, H Reichenspumer, BM Meiser, A Welz, H Fiirst, C Miiller, et al.
Tacrolimus (FK506) as primary immunosuppressant after lung transplantation.
Thorac Cardiovasc Surg, 47 (1999), pp. 174-178
[24]
YM Cho, KS Park, HS Jung, HJ Jean, C Ahn, J Ha, et al.
High incidence of tacrolimus-associated posttransplantation diabetes in the Korean renal allograft recipients according to American Diabetes Association criteria.
Diabetes Care, 26 (2003), pp. 1123-1128
[25]
J Oberholzer, J Thielke, B Hatipoglu, G Testa, HN Sankary, E Benedetti.
Immediate conversion from tacrolimus to cyclosporine in the treatment of posttransplantation diabetes mellitus.
Transplant Proc, 37 (2005), pp. 999-1000
[26]
M Roy First.
Tacrolimus based immunosuppression.
J Nephrol, 17 (2004), pp. 25-31
Copyright © 2007. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?